Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases

Drug Delivery and Translational Research
Christopher D HerzogRaymond T Bartus

Abstract

Efforts to develop neurotrophic factors to restore function and protect dying neurons in chronic neurodegenerative diseases like Alzheimer's (AD) and Parkinson's (PD) have been attempted for decades. Despite abundant data establishing nonclinical proof-of-concept, significant delivery issues have precluded the successful translation of this concept to the clinic. The development of AAV2 viral vectors to deliver therapeutic genes has emerged as a safe and effective means to achieve sustained, long-term, targeted, bioactive protein expression. Thus, it potentially offers a practical means to solve those long-standing delivery/translational issues associated with neurotrophic factors. Data are presented for two AAV2 viral vector constructs expressing one of two different neurotrophic factors: nerve growth factor (NGF) and neurturin (NRTN). One (AAV2-NGF; aka CERE-110) is being developed as a treatment to improve the function and delay further degeneration of cholinergic neurons in the nucleus basalis of Meynert, the degeneration of which has been linked to cognitive deficits in AD. The other (AAV2-NRTN; aka CERE-120) is similarly being developed to treat the degenerating nigrostriatal dopamine neurons and major motor deficits in P...Continue Reading

References

Oct 1, 1989·Annals of Neurology·W D Snider, E M Johnson
Jan 1, 1986·Annual Review of Physiology·F H Gage, A Björklund
Jul 30, 1982·Science·R T BartusA S Lippa
Nov 8, 1994·Proceedings of the National Academy of Sciences of the United States of America·J H KordowerD F Emerich
Mar 29, 1996·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·S B McMahon
Oct 1, 1996·Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology·J C PettersenD R Schwartz
Mar 6, 1998·Nature Biotechnology·S D Putney, P A Burke
Aug 14, 1998·Dementia and Geriatric Cognitive Disorders·M Eriksdotter JönhagenL O Wahlund
Sep 12, 1998·Science·R T BartusS E Zale
Oct 8, 1998·The New England Journal of Medicine·A E Lang, A M Lozano
Oct 15, 1998·The New England Journal of Medicine·A E Lang, A M Lozano
Sep 15, 1999·Proceedings of the National Academy of Sciences of the United States of America·D E SmithM H Tuszynski
Aug 25, 2001·Annual Review of Neuroscience·E J Huang, L F Reichardt
Aug 25, 2001·Annual Review of Neuroscience·M V SofroniewW C Mobley
Jan 15, 2003·Neurology·J G NuttUNKNOWN ICV GDNF Study Group. Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor
Feb 14, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Todd B ShererJ William Langston
Mar 15, 2006·The Journal of Gene Medicine·S W J McPheeP Leone
Jun 17, 2006·Annual Review of Neuroscience·Sophie Pezet, Stephen B McMahon
Sep 12, 2006·Experimental Neurology·Michael F SalvatoreDon M Gash
Dec 14, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mehdi GasmiRaymond T Bartus
Apr 20, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher D HerzogJeffrey H Kordower

❮ Previous
Next ❯

Citations

Dec 21, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Raymond T BartusR Jude Samulski
Jan 15, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Michael S RafiiRaymond T Bartus
Dec 12, 2012·Expert Opinion on Biological Therapy·Patrick Hickey, Mark Stacy
Jul 2, 2016·Pharmacological Reports : PR·Ewa A OgłodekAleksander Araszkiewicz
Feb 8, 2018·Human Gene Therapy. Clinical Development·Jonathan B RosenbergRonald G Crystal
Mar 24, 2020·Brain : a Journal of Neurology·Yaping ChuJeffrey H Kordower
Aug 9, 2020·Acta Neuropathologica Communications·Francesca VitaleCristina d'Abramo
Aug 24, 2018·Acta Neuropathologica Communications·Francesca VitaleCristina d'Abramo
May 30, 2017·Neural Regeneration Research·Tuane Bazanella SampaioSimone Pinton
Mar 20, 2020·Physiological Reviews·Sonja KleinlogelTobias Moser
Jan 1, 2019·Expert Opinion on Orphan Drugs·Jonathan B RosenbergDolan Sondhi
Jun 21, 2020·Neuroscience Letters·Ifeoluwa Oluleke AwogbindinMarie-Ève Tremblay
Jul 3, 2021·International Journal of Molecular Sciences·Ana Fajardo-SerranoJosé Luis Lanciego

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.